Characterization of Epigenetic Drug Discovery Epigenetic modifications such as DNA methylation, histone methylation, and deacetylation have been demonstrated to regulate a wide range of physiological and pathological processes. It is also well established that epigenetic alterations can be used as the biomarkers and therapeutic targets in many diseases, especially cancer. This has led drug and biotechnology companies to actively search for intervention agents of epigenetic alterations. To better meet your needs at each stage of drug discovery continuum, Epigentek now offers its service for the discovery of drugs that aim at epigenetic targets. Our services will enable you to: Enhance your drug discovery and development without the burden of increased staff and equipment. Choose better drug candidates for further development. Determine specificity of the lead candidates against a wide range of epigenetic targets. Validate the lead candidates in a rapid, reliable, and high throughput assay format. Our discovery service platforms include: Epigenase™ Epigenetic Enzyme Inhibitor Screening System EpiModifer™ Epigenetic Modulator Screening System These screening systems can enable the drug candidates to be tested in situ and in vitro. Contact us at services@epigentek.com